Atherosclerosis - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 288 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Atherosclerosis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Atherosclerosis - Pipeline Review, H2 2014', provides an overview of the Atherosclerosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Atherosclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atherosclerosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Atherosclerosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Atherosclerosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Atherosclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Atherosclerosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Atherosclerosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Atherosclerosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Atherosclerosis Overview 11
Therapeutics Development 12
Pipeline Products for Atherosclerosis - Overview 12
Pipeline Products for Atherosclerosis - Comparative Analysis 13
Atherosclerosis - Therapeutics under Development by Companies 14
Atherosclerosis - Therapeutics under Investigation by Universities/Institutes 20
Atherosclerosis - Pipeline Products Glance 23
Late Stage Products 23
Clinical Stage Products 24
Early Stage Products 25
Atherosclerosis - Products under Development by Companies 26
Atherosclerosis - Products under Investigation by Universities/Institutes 31
Atherosclerosis - Companies Involved in Therapeutics Development 34
Aastrom Biosciences, Inc. 34
Ache Laboratorios Farmaceuticos S/A 35
advanceCor GmbH 36
AFFiRiS AG 37
Arisaph Pharmaceuticals, Inc. 38
Artery Therapeutics, Inc. 39
AstraZeneca PLC 40
Athera Biotechnologies AB 41
AtheroNova Inc. 42
AuraSense Therapeutics, LLC 43
Bayer AG 44
Boehringer Ingelheim GmbH 45
Bridge Bioresearch Plc 46
Bristol-Myers Squibb Company 47
Cardax Pharmaceuticals, Inc. 48
ChemoCentryx, Inc. 49
CIMAB S.A. 50
CSL Limited 51
DoNatur GmbH 52
Dr. Reddy's Laboratories Limited 53
Dybly AG 54
Eli Lilly and Company 55
F. Hoffmann-La Roche Ltd. 56
Galapagos NV 57
GenKyoTex S.A. 58
GlaxoSmithKline plc 59
Isis Pharmaceuticals, Inc. 60
Johnson & Johnson 61
KineMed, Inc. 62
Kowa Company, Ltd. 63
Lead Discovery Center GmbH 64
MedImmune, LLC 65
Merck & Co., Inc. 66
MI.TO. Technology S.r.L. 67
NasVax Ltd. 68
Novartis AG 69
Omeros Corporation 70
OPKO Health, Inc. 71
Otsuka Holdings Co., Ltd. 72
Phenex Pharmaceuticals AG 73
Provid Pharmaceuticals, Inc. 74
Resverlogix Corp. 75
SelectX Pharmaceuticals, Inc. 76
The Medicines Company 77
Vascular Biogenics Ltd. 78
Vascular Pharmaceuticals, Inc. 79
Vitae Pharmaceuticals, Inc. 80
Zydus Cadila Healthcare Limited 81
Atherosclerosis - Therapeutics Assessment 82
Assessment by Monotherapy Products 82
Assessment by Target 83
Assessment by Mechanism of Action 87
Assessment by Route of Administration 91
Assessment by Molecule Type 93
Drug Profiles 96
AEM-28 - Drug Profile 96
AG-01 - Drug Profile 97
AHRO-001 - Drug Profile 98
AHRO-002 - Drug Profile 100
AHRO-003 - Drug Profile 101
aliskiren fumarate - Drug Profile 102
AM-0010 - Drug Profile 104
anacetrapib - Drug Profile 105
Annexin A-5 - Drug Profile 107
Anti-CD3 Oral Immunotherapy - Drug Profile 109
Antibody to Target CD97 for Inflammation and Atherosclerosis - Drug Profile 111
Antisense Oligonucleotide to Inhibit Cide B for Hyperlipidemia and Atherosclerosis - Drug Profile 112
ARI-1778 - Drug Profile 113
Artpep-2 - Drug Profile 114
ATH-03 - Drug Profile 115
AZ-876 - Drug Profile 116
BAY-606583 - Drug Profile 117
Biglycan Therapy for Cardiovascular Diseases - Drug Profile 118
BSN-272 - Drug Profile 119
BSN-723 - Drug Profile 120
CB-102 - Drug Profile 121
CCX-771 - Drug Profile 122
CCX-872 - Drug Profile 123
CD14 Project - Drug Profile 124
CDX-085 - Drug Profile 125
COR-2 - Drug Profile 127
CSL-112 - Drug Profile 128
cSN-50 - Drug Profile 129
CSN-501 - Drug Profile 131
CVX-210H - Drug Profile 132
D-4F - Drug Profile 133
darapladib - Drug Profile 134
DRL-17822 - Drug Profile 136
Drug for Atherosclerosis - Drug Profile 137
Drug for Atherosclerotic Plaque - Drug Profile 138
Drugs to Antagonize NMDA Receptor for Atherosclerosis - Drug Profile 139
DYB-186 - Drug Profile 140
E06-ScFV - Drug Profile 141
EP-80317 - Drug Profile 142
evacetrapib - Drug Profile 143
FX-141L - Drug Profile 145
FX-5A - Drug Profile 146
FX-87L - Drug Profile 147
Gene Therapy for Arteriosclerosis and Endothelial Dysfunction - Drug Profile 148
Gene Therapy for Atherosclerosis - Drug Profile 149
Gene Therapy to Target miR-145 for Atherosclerosis - Drug Profile 150
GKT-136901 - Drug Profile 151
GKT-137831 - Drug Profile 153
GQ-16 - Drug Profile 154
GYY-4137 - Drug Profile 155
INV-88 - Drug Profile 157
ISIS-APOARx - Drug Profile 158
ixmyelocel-T - Drug Profile 159
K-312 - Drug Profile 162
K-877 - Drug Profile 163
KM-011 - Drug Profile 165
KRP-206 - Drug Profile 166
LDN-193189 - Drug Profile 167
LPC-01 - Drug Profile 168
LYP-1 Peptide for Atherosclerosis - Drug Profile 169
MCS-18 - Drug Profile 170
MDCO-216 - Drug Profile 172
MEDI-6012 - Drug Profile 174
melittin - Drug Profile 176
Monoclonal Antibody to Inhibit CD20 for Cardiovascular Disease - Drug Profile 177
Monoclonal Antibody to Inhibit Endothelial Lipase for Atherosclerosis - Drug Profile 178
Nanotherapeutics - Drug Profile 179
Next Generation Lecinoxoids - Drug Profile 180
PC-mAb - Drug Profile 181
Peptides to Inhibit Calcineurin for Rheumatoid Arthritis and Atherosclerosis - Drug Profile 183
Progranulin - Drug Profile 184
Protein for Atherosclerosis - Drug Profile 185
Protein to Agonize SRB1 for Atherosclerosis and Lymphoma - Drug Profile 186
PX-20606 - Drug Profile 188
Recombinant Peptide for Atherosclorosis - Drug Profile 190
Recombinant Proteins to Inhibit Serine Protease for Thrombosis, Ischemic Stroke and Atherosclerosis - Drug Profile 191
RNAi Gene Therapy to Inhibit STIM1 for Cardiovascular Diseases - Drug Profile 192
RNAi Oligonucleotide to Inhibit STIM1 for Cardiovascular Disorders - Drug Profile 194
RO-6836191 - Drug Profile 195
rPAI-123 - Drug Profile 196
RVX-208 - Drug Profile 197
Small Molecule for Atherosclerosis - Drug Profile 199
Small Molecule for Atherosclerosis - Drug Profile 200
Small Molecule for Atherosclerosis and Insulin Resistance - Drug Profile 201
Small Molecule Target GPR176 for Atherosclerosis - Drug Profile 202
Small Molecule to Activate NF-E2 Related Factor 2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology - Drug Profile 203
Small Molecule to Inhibit IKK and TBK1 for Cardiovascular, Gastrointestinal and Metabolic Disorders - Drug Profile 204
Small Molecule to Inhibit NOX 1 and 4 - Drug Profile 205
Small Molecule to Target GPR132 for Atherosclerosis - Drug Profile 206
Small Molecules for Atherosclerosis - Drug Profile 207
Small Molecules for Atherosclerosis and Obesity - Drug Profile 208
Small Molecules for Inflammatory and Metabolic Diseases - Drug Profile 209
Small Molecules for Inflammatory Diseases - Drug Profile 210
Small Molecules for Metabolic, Cardiovascular and Inflammatory Disease - Drug Profile 211
Small Molecules for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders - Drug Profile 212
Small Molecules to Activate CB2 for Atherosclerosis and Rheumatoid Arthritis - Drug Profile 214
Small Molecules to Inhibit BMP4 for Immunology and Cardiovascular Disorders - Drug Profile 215
Small Molecules to Inhibit Cell Migration - Drug Profile 216
Small Molecules to Inhibit Chymase for Atherosclerosis - Drug Profile 217
Small Molecules to Inhibit Lipase for Atherosclerosis - Drug Profile 218
Small Molecules to Inhibit Lipoxygenase for Oncology, Cardiovascular and Respiratory Disorders - Drug Profile 219
SPX-7233801 - Drug Profile 220
Stem Cell Therapy for Atherosclerosis - Drug Profile 221
SYN-20110119RU - Drug Profile 222
Synthetic Peptide to Inhibit F11R for Atherosclerosis - Drug Profile 223
Synthetic Peptides to Activate Apolipoprotein for Atherosclerosis and Inflammation - Drug Profile 225
Vaccine for Atherosclerosis - Drug Profile 226
Vaccine for Atherosclerosis - Drug Profile 227
Vaccine for Atherosclerosis - Drug Profile 228
Vaccine to Target Angiotensin II for Cardiovascular Diseases - Drug Profile 229
Vaccine to Target PCSK9 for Atherosclerosis - Drug Profile 230
VB-201 - Drug Profile 231
VPI-2690-B - Drug Profile 233
VTP-4 - Drug Profile 235
XL-652 - Drug Profile 236
Atherosclerosis - Recent Pipeline Updates 238
Atherosclerosis - Dormant Projects 263
Atherosclerosis - Discontinued Products 266
Atherosclerosis - Product Development Milestones 267
Featured News & Press Releases 267
Appendix 279
Methodology 279
Coverage 279
Secondary Research 279
Primary Research 279
Expert Panel Validation 279
Contact Us 280
Disclaimer 280

List of Tables
Number of Products under Development for Atherosclerosis, H2 2014 20
Number of Products under Development for Atherosclerosis - Comparative Analysis, H2 2014 21
Number of Products under Development by Companies, H2 2014 23
Number of Products under Development by Companies, H2 2014 (Contd..1) 24
Number of Products under Development by Companies, H2 2014 (Contd..2) 25
Number of Products under Development by Companies, H2 2014 (Contd..3) 26
Number of Products under Development by Companies, H2 2014 (Contd..4) 27
Number of Products under Investigation by Universities/Institutes, H2 2014 29
Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 30
Comparative Analysis by Late Stage Development, H2 2014 31
Comparative Analysis by Clinical Stage Development, H2 2014 32
Comparative Analysis by Early Stage Development, H2 2014 33
Products under Development by Companies, H2 2014 34
Products under Development by Companies, H2 2014 (Contd..1) 35
Products under Development by Companies, H2 2014 (Contd..2) 36
Products under Development by Companies, H2 2014 (Contd..3) 37
Products under Development by Companies, H2 2014 (Contd..4) 38
Products under Investigation by Universities/Institutes, H2 2014 39
Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 40
Products under Investigation by Universities/Institutes, H2 2014 (Contd..2) 41
Atherosclerosis - Pipeline by Aastrom Biosciences, Inc., H2 2014 42
Atherosclerosis - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2014 43
Atherosclerosis - Pipeline by advanceCor GmbH, H2 2014 44
Atherosclerosis - Pipeline by AFFiRiS AG, H2 2014 45
Atherosclerosis - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2014 46
Atherosclerosis - Pipeline by Artery Therapeutics, Inc., H2 2014 47
Atherosclerosis - Pipeline by AstraZeneca PLC, H2 2014 48
Atherosclerosis - Pipeline by Athera Biotechnologies AB, H2 2014 49
Atherosclerosis - Pipeline by AtheroNova Inc., H2 2014 50
Atherosclerosis - Pipeline by AuraSense Therapeutics, LLC, H2 2014 51
Atherosclerosis - Pipeline by Bayer AG, H2 2014 52
Atherosclerosis - Pipeline by Boehringer Ingelheim GmbH, H2 2014 53
Atherosclerosis - Pipeline by Bridge Bioresearch Plc, H2 2014 54
Atherosclerosis - Pipeline by Bristol-Myers Squibb Company, H2 2014 55
Atherosclerosis - Pipeline by Cardax Pharmaceuticals, Inc., H2 2014 56
Atherosclerosis - Pipeline by ChemoCentryx, Inc., H2 2014 57
Atherosclerosis - Pipeline by CIMAB S.A., H2 2014 58
Atherosclerosis - Pipeline by CSL Limited, H2 2014 59
Atherosclerosis - Pipeline by DoNatur GmbH, H2 2014 60
Atherosclerosis - Pipeline by Dr. Reddy's Laboratories Limited, H2 2014 61
Atherosclerosis - Pipeline by Dybly AG, H2 2014 62
Atherosclerosis - Pipeline by Eli Lilly and Company, H2 2014 63
Atherosclerosis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 64
Atherosclerosis - Pipeline by Galapagos NV, H2 2014 65
Atherosclerosis - Pipeline by GenKyoTex S.A., H2 2014 66
Atherosclerosis - Pipeline by GlaxoSmithKline plc, H2 2014 67
Atherosclerosis - Pipeline by Isis Pharmaceuticals, Inc., H2 2014 68
Atherosclerosis - Pipeline by Johnson & Johnson, H2 2014 69
Atherosclerosis - Pipeline by KineMed, Inc., H2 2014 70
Atherosclerosis - Pipeline by Kowa Company, Ltd., H2 2014 71
Atherosclerosis - Pipeline by Lead Discovery Center GmbH, H2 2014 72
Atherosclerosis - Pipeline by MedImmune, LLC, H2 2014 73
Atherosclerosis - Pipeline by Merck & Co., Inc., H2 2014 74
Atherosclerosis - Pipeline by MI.TO. Technology S.r.L., H2 2014 75
Atherosclerosis - Pipeline by NasVax Ltd., H2 2014 76
Atherosclerosis - Pipeline by Novartis AG, H2 2014 77
Atherosclerosis - Pipeline by Omeros Corporation, H2 2014 78
Atherosclerosis - Pipeline by OPKO Health, Inc., H2 2014 79
Atherosclerosis - Pipeline by Otsuka Holdings Co., Ltd., H2 2014 80
Atherosclerosis - Pipeline by Phenex Pharmaceuticals AG, H2 2014 81
Atherosclerosis - Pipeline by Provid Pharmaceuticals, Inc., H2 2014 82
Atherosclerosis - Pipeline by Resverlogix Corp., H2 2014 83
Atherosclerosis - Pipeline by SelectX Pharmaceuticals, Inc., H2 2014 84
Atherosclerosis - Pipeline by The Medicines Company, H2 2014 85
Atherosclerosis - Pipeline by Vascular Biogenics Ltd., H2 2014 86
Atherosclerosis - Pipeline by Vascular Pharmaceuticals, Inc., H2 2014 87
Atherosclerosis - Pipeline by Vitae Pharmaceuticals, Inc., H2 2014 88
Atherosclerosis - Pipeline by Zydus Cadila Healthcare Limited, H2 2014 89
Assessment by Monotherapy Products, H2 2014 90
Number of Products by Stage and Target, H2 2014 93
Number of Products by Stage and Mechanism of Action, H2 2014 97
Number of Products by Stage and Route of Administration, H2 2014 100
Number of Products by Stage and Molecule Type, H2 2014 103
Atherosclerosis Therapeutics - Recent Pipeline Updates, H2 2014 246
Atherosclerosis - Dormant Projects, H2 2014 271
Atherosclerosis - Discontinued Products, H2 2014 274